JP2015020949A - HAIR COSMETIC AND SKIN COSMETIC CONTAINING PGD2 PRODUCTION INHIBITOR AND 5α-REDUCTASE ACTIVITY INHIBITOR - Google Patents
HAIR COSMETIC AND SKIN COSMETIC CONTAINING PGD2 PRODUCTION INHIBITOR AND 5α-REDUCTASE ACTIVITY INHIBITOR Download PDFInfo
- Publication number
- JP2015020949A JP2015020949A JP2013147341A JP2013147341A JP2015020949A JP 2015020949 A JP2015020949 A JP 2015020949A JP 2013147341 A JP2013147341 A JP 2013147341A JP 2013147341 A JP2013147341 A JP 2013147341A JP 2015020949 A JP2015020949 A JP 2015020949A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- pgd
- hair
- inhibitor
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 88
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 76
- 239000002537 cosmetic Substances 0.000 title claims abstract description 49
- 230000000694 effects Effects 0.000 title claims abstract description 43
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 title claims abstract description 36
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 title description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 title 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 title 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 84
- 239000000419 plant extract Substances 0.000 claims abstract description 19
- 241000508269 Psidium Species 0.000 claims abstract description 10
- 229940109529 pomegranate extract Drugs 0.000 claims abstract description 9
- 229940112950 sage extract Drugs 0.000 claims abstract description 8
- 235000020752 sage extract Nutrition 0.000 claims abstract description 8
- 235000020748 rosemary extract Nutrition 0.000 claims abstract description 7
- 229940092258 rosemary extract Drugs 0.000 claims abstract description 7
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims abstract description 7
- 229940007062 eucalyptus extract Drugs 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 17
- 239000003676 hair preparation Substances 0.000 claims description 11
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 10
- 241000546188 Hypericum Species 0.000 claims description 9
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 9
- 244000223014 Syzygium aromaticum Species 0.000 claims description 9
- 240000002657 Thymus vulgaris Species 0.000 claims description 9
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 9
- 239000001585 thymus vulgaris Substances 0.000 claims description 9
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 4
- 240000006891 Artemisia vulgaris Species 0.000 claims description 3
- 239000010330 ougon Substances 0.000 claims description 2
- 241000287462 Phalacrocorax carbo Species 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 23
- 201000004384 Alopecia Diseases 0.000 abstract description 21
- 208000024963 hair loss Diseases 0.000 abstract description 20
- 230000003676 hair loss Effects 0.000 abstract description 19
- 230000003750 conditioning effect Effects 0.000 abstract description 14
- 241000546193 Clusiaceae Species 0.000 abstract 1
- 241000628997 Flos Species 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 109
- 210000003491 skin Anatomy 0.000 description 47
- 230000000052 comparative effect Effects 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 238000000605 extraction Methods 0.000 description 24
- 239000007864 aqueous solution Substances 0.000 description 22
- 241000196324 Embryophyta Species 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 238000004108 freeze drying Methods 0.000 description 14
- 239000008213 purified water Substances 0.000 description 14
- -1 etc.) Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 10
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 10
- 229960002216 methylparaben Drugs 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- 239000002453 shampoo Substances 0.000 description 9
- 244000166124 Eucalyptus globulus Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 235000015961 tonic Nutrition 0.000 description 7
- 230000001256 tonic effect Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 208000006981 Skin Abnormalities Diseases 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 230000003813 thin hair Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 244000294611 Punica granatum Species 0.000 description 3
- 235000014360 Punica granatum Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940043375 1,5-pentanediol Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 241000092668 Artemisia capillaris Species 0.000 description 2
- 235000008658 Artemisia capillaris Nutrition 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 244000030166 artemisia Species 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229940105902 mint extract Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 1
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001273783 Carex scoparia Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000107602 Corymbia citriodora Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 235000004722 Eucalyptus citriodora Nutrition 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 235000006647 Eugenia jambos Nutrition 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000001679 Psidium guajava Species 0.000 description 1
- 235000013929 Psidium pyriferum Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 244000087016 Syzygium jambos Species 0.000 description 1
- 235000017715 Thymus pulegioides Nutrition 0.000 description 1
- 240000006001 Thymus serpyllum Species 0.000 description 1
- 235000004054 Thymus serpyllum Nutrition 0.000 description 1
- 241001184553 Thymus x citriodorus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、ＰＧＤ2産生抑制剤と５α−リダクターゼ活性阻害剤とを含有し、優れた脱毛抑制作用及び整肌作用を有する頭髪化粧料及び皮膚化粧料に関する。 The present invention relates to a hair cosmetic and a skin cosmetic that contain a PGD 2 production inhibitor and a 5α-reductase activity inhibitor and have an excellent hair loss inhibiting action and skin conditioning action.
脱毛や薄毛は、性ホルモン、ストレス、遺伝、加齢等のさまざまな原因が複雑に関与しているといわれている。なかでも男性ホルモンの影響による男性型脱毛症（以下、ＡＧＡとする）は広く知られており、加齢等により女性ホルモンの分泌が減少することで、相対的に男性ホルモンが優位になること等により、男性だけではなく女性にも生じる。 It is said that a variety of causes such as sex hormones, stress, heredity, and aging are involved in hair loss and thinning hair in a complex manner. In particular, male pattern baldness (hereinafter referred to as AGA) due to the effects of male hormones is widely known, and the secretion of female hormones decreases due to aging, etc., and male hormones are relatively dominant. This occurs not only for men but also for women.
ＡＧＡの発症には男性ホルモンの１種であるテストステロンが関与していると言われている。テストステロンは、還元酵素であるテストステロン５α−リダクターゼにより還元され、ジヒドロテストステロン（以下、ＤＨＴとする）に変化し、アンドロゲンレセプターに結合する。その結果、毛周期の退行期が誘導され成長期が通常より短くなることにより軟毛化し、頭頂部や前頭部の毛髪が薄くなったり脱毛すると言われている。 It is said that testosterone, a type of male hormone, is involved in the development of AGA. Testosterone is reduced by the reductase testosterone 5α-reductase, converted to dihydrotestosterone (hereinafter referred to as DHT), and binds to the androgen receptor. As a result, it is said that the regression period of the hair cycle is induced and the growth period becomes shorter than usual, so that the hair becomes soft and the hair on the top of the head or the frontal region becomes thinner or loses hair.
よって、５α−リダクターゼ活性を阻害することはＡＧＡの抑制に有効であり、５α−リダクターゼ活性阻害効果を高めるための様々な方法が提案されている（特許文献１、特許文献２）。
しかしながら、これらの方法をもってしても薄毛や脱毛の改善は十分なものではなかった。
Therefore, inhibiting 5α-reductase activity is effective in suppressing AGA, and various methods for enhancing the 5α-reductase activity inhibitory effect have been proposed (Patent Documents 1 and 2).
However, even with these methods, improvement in thinning and hair loss has not been sufficient.
ところで近年、生理活性物質のプロスタグランジンＤ2（以下、ＰＧＤ2とする）の発現量がＡＧＡ発症部位で高くなっていることが発見され（非特許文献１）、ＡＧＡとＰＧＤ2産生に関係があることが示唆されている。ＰＧＤ2は、一般的なアレルギー炎症であるＩ型アレルギー反応においてマスト細胞から分泌されるものである。ＰＧＤ2産生を抑制することによりＡＧＡの抑制を図ることが考えられており、ＰＧＤ2産生抑制成分として例えば特許文献３にシナモン成分等が記載されている。
しかしながら、これらの成分によるＡＧＡ抑制は未だ不十分であり、ＡＧＡ抑制に有効なＰＧＤ2産生抑制物質はほとんど知られていない。
Recently, it has been discovered that the expression level of the bioactive substance prostaglandin D 2 (hereinafter referred to as PGD 2 ) is high at the AGA onset site (Non-Patent Document 1), and is related to AGA and PGD 2 production. It is suggested that there is. PGD 2 is secreted from mast cells in the type I allergic reaction, which is a general allergic inflammation. It is thought it possible to AGA suppression by inhibiting PGD 2 production, cinnamon component such as for example, Patent Document 3 as PGD 2 production inhibitory ingredients.
However, AGA suppression by these components is still insufficient, and almost no PGD 2 production inhibitor effective for AGA suppression is known.
また、今日では社会環境や食生活の変化を背景に、生活パターンが著しく変化し、これに起因する生活ストレスが急増していると言われている。かかるストレスが背景となって、皮膚のかぶれや湿疹等アレルギーによる皮膚の各種炎症や、原因不明の肌荒れに悩む人が急増している。このような肌荒れの改善方法として、上述のＰＧＤ2産生抑制成分を含む組成物（特許文献３）や抗炎症作用を有する植物抽出物を含有する皮膚外用剤（特許文献４）が提案されている。
しかしながら、原因が複雑化した今日の肌荒れの改善には未だ不十分であり、より優れた整肌作用を有する皮膚化粧料が望まれていた。
In addition, today, it is said that life patterns have changed remarkably against the background of changes in the social environment and dietary habits, and life stress resulting from this has increased rapidly. Against this background, the number of people suffering from various skin irritation caused by skin allergies such as skin irritation and eczema and rough skin for unknown causes is increasing rapidly. As a method for improving such rough skin, a composition containing the above-described PGD 2 production inhibitor (Patent Document 3) and an external preparation for skin containing a plant extract having an anti-inflammatory action (Patent Document 4) have been proposed. .
However, it is still insufficient for the improvement of today's rough skin whose causes are complicated, and a skin cosmetic having a better skin conditioning action has been desired.
本発明は、上記課題に鑑みてなされたものであり、ＡＧＡとの関係が示唆され、加えて炎症時に発現量が高くなるＰＧＤ2の産生を抑制することにより、優れた脱毛抑制作用及び整肌作用を達成するＰＧＤ2産生抑制剤並びにこれと５α−リダクターゼ活性阻害剤とを含有する頭髪化粧料及び皮膚化粧料を提供することを目的とする。 The present invention has been made in view of the above problems, suggests a relationship with AGA, and in addition, suppresses the production of PGD 2 whose expression level is high during inflammation, thereby providing an excellent hair loss inhibiting action and skin conditioning. It is an object of the present invention to provide a hair cosmetic and a skin cosmetic containing a PGD 2 production inhibitor that achieves the action, and a 5α-reductase activity inhibitor.
本発明者らは、上記課題を解決するために鋭意研究を重ねた結果、特定の植物抽出物を用いることにより優れたＰＧＤ2産生抑制効果が得られることを見出した。また、そのＰＧＤ2産生抑制効果により得られる脱毛抑制作用及び整肌作用が、５α−リダクターゼ活性阻害剤を併用することにより非常に向上することを見出し、これらの知見に基づき本発明を完成させた。 As a result of intensive studies to solve the above problems, the present inventors have found that an excellent PGD 2 production inhibitory effect can be obtained by using a specific plant extract. In addition, it has been found that the hair loss inhibitory action and skin conditioning action obtained by the PGD 2 production inhibitory effect are greatly improved by using a 5α-reductase activity inhibitor in combination, and the present invention has been completed based on these findings. .
すなわち、本発明は、ローズマリー抽出物、タイム抽出物、カワラヨモギ抽出物、オウゴン抽出物、ユーカリ抽出物からなる群より選ばれる少なくとも１種の植物抽出物を含有することを特徴とするＰＧＤ2産生抑制剤を提供するものである。
また本発明は、前記ＰＧＤ2産生抑制剤と５α−リダクターゼ活性阻害剤とを含有することを特徴とする頭髪化粧料及び皮膚化粧料を提供するものである。
That is, the present invention contains PGD 2 production characterized in that it contains at least one plant extract selected from the group consisting of rosemary extract, thyme extract, kawara mugi extract, ougon extract, eucalyptus extract. An inhibitor is provided.
The present invention is to provide a hair cosmetic and skin cosmetic which is characterized by containing said PGD 2 production inhibitor and 5α- reductase activity inhibitors.
また、前記頭髪化粧料及び皮膚化粧料においては、前記５α−リダクターゼ活性阻害剤が、ザクロ抽出物、チョウジ抽出物、オトギリソウ抽出物、グアバ抽出物、セージ抽出物からなる群より選ばれる少なくとも１種の植物抽出物を含有していることが好ましい。 In the hair cosmetics and skin cosmetics, the 5α-reductase activity inhibitor is at least one selected from the group consisting of pomegranate extract, clove extract, hypericum extract, guava extract, and sage extract. It is preferable that the plant extract is contained.
本発明のＰＧＤ2産生抑制剤は、ＡＧＡとの関係が示唆されているＰＧＤ2産生を抑制するため、これを用いて脱毛や薄毛、特にＡＧＡの改善を図ることができる。また、これを配合することにより、優れた脱毛作用を有する頭髪化粧料を提供することができる。 PGD 2 production inhibitor of the present invention, in order to suppress the PGD 2 production relationship between AGA has been suggested, hair loss and thinning hair by using this, it is possible to particularly improve the AGA. Moreover, the hair cosmetics which have the outstanding hair removal action can be provided by mix | blending this.
また、本発明のＰＧＤ2産生抑制剤は、炎症時に発現量が高くなるＰＧＤ2の産生を抑制することもできるため、これを用いて肌荒れの改善を図ることができる。また、これを配合することにより優れた整肌作用を有する皮膚化粧料を提供することができる。 Further, PGD 2 production inhibitor of the present invention, since it is also possible to suppress the production of PGD 2 expression level during inflammation increases, it is possible to improve the skin roughness by using this. Moreover, the skin cosmetics which have the outstanding skin conditioning effect | action by mix | blending this can be provided.
本発明のＰＧＤ2産生抑制剤は、ローズマリー抽出物、タイム抽出物、カワラヨモギ抽出物、オウゴン抽出物、ユーカリ抽出物からなる群より選ばれる少なくとも１種の植物抽出物を含有する。 The PGD 2 production inhibitor of the present invention contains at least one plant extract selected from the group consisting of a rosemary extract, a thyme extract, a Chinese mugwort extract, an ogon extract, and a eucalyptus extract.
これらの植物抽出物は、いずれも医薬又は民間薬、食品、化粧品の成分として一般的に用いられているものである。
中でも、ＰＧＤ2産生抑制効果がより優れているという観点から、ローズマリー抽出物、タイム抽出物及びカワラヨモギ抽出物の１種または２種以上を含有することが好ましい。
All of these plant extracts are commonly used as components of medicines or folk medicines, foods, and cosmetics.
Among them, from the viewpoint of PGD 2 production inhibitory effect is better, rosemary extract, preferably contains one or more thyme extract and Artemisia capillaris extract.
本発明におけるローズマリー抽出物とは、シソ科ロスマリヌス属ローズマリー（Ｒｏｓ
ｍａｒｉｎｕｓ Ｏｆｆｉｃｉｎａｌｉｓ）から抽出されて得られる抽出物を言う。抽出には全草、または地上部、茎や葉等の地上部の各部位を使用してもよいが、葉を使用することが好ましい。
The rosemary extract in the present invention is a rosinus genus rosemary (Ros).
The extract obtained by extracting from Marinus Officinalis). For extraction, the whole plant, or each part of the above-ground part such as the above-ground part, stem, and leaf may be used, but it is preferable to use the leaf.
本発明におけるタイム抽出物とは、タイム（Ｔｈｙｍｕ）から抽出されて得られる抽出物を言う。タイムとはシソ科イブキジャコウソウ属の植物の総称であり、そのような植物としては、例えば、タチジャコウソウ（Ｔｈｙｍｕｓ ｖｕｌｇａｒｉｓ、別名：コモンタイム）、イブキジャコウソウ（Ｔｈｙｍｕｓ ｓｅｒｐｙｌｌｕｍ ｓｓｐ．ｑｕｉｎｑｕｅｃｏｓｔａｔｕｓ）、ヨウシュイブキジャコウソウ（Ｔｈｙｍｕｓ ｓｅｒｐｙｌｌｕｍ、別名：ワイルドタイム、クリーピングタイム）、シトラスタイム（Ｔｈｙｍｕｓ
ｘ ｃｉｔｒｉｏｄｏｒｕｓ、別名：レモンタイム）等がある。中でも、タチジャコウソウが好ましい。
The thyme extract in the present invention refers to an extract obtained by extraction from thyme. Thyme is a collective term for plants belonging to the genus Lamiaceae, and examples of such plants include Thymus vulgaris (also known as common time), Thymus serpylum ssp. Quinquecostatus, (Thymus serpylum, aka: Wild Time, Creeping Time), Citrus Time (Thymus
x citriodorus, also known as: lemon thyme). Of these, Tachijasou is preferable.
抽出には全草、またはその地上部、茎や葉等地上部の各部位を使用してもよいが、花、茎、葉を使用することが好ましい。
本発明におけるカワラヨモギ抽出物とは、キク科ヨモギ属の植物の一種であるカワラヨモギ（Ａｒｔｅｍｉｓｉａ ｃａｐｉｌｌａｒｉｓ Ｔｈｕｎｂ．）から得られる抽出物を言う。
For the extraction, the whole plant or each part of the above-ground part such as the above-ground part, stem and leaf may be used, but it is preferable to use flowers, stems and leaves.
The Kawara mugwort extract in the present invention refers to an extract obtained from Artemisia capillaris chumb. Which is a kind of plant belonging to the genus Artemisia.
抽出には全草、またはその地上部、茎、葉、花、花蕾等地上部の各部位を使用してもよいが、中でも花を使用することが好ましい。また、生薬「インチンコウ」を用いても良い。さらに、同属植物を用いることもできる。 For the extraction, the whole plant, or each part of the above-ground part such as the above-ground part, stem, leaf, flower, and floret may be used, but among them, it is preferable to use a flower. Alternatively, the herbal medicine “Inchinkou” may be used. Furthermore, plants belonging to the same genus can also be used.
本発明におけるオウゴン抽出物とは、シソ科タツナミソウ属の植物の一種であるコガネバナ（Ｓｃｕｔｅｌｌａｒｉａ ｂａｉｃａｌｅｎｓｉｓ Ｇｅｏｒｇｉ）の根から抽出されて得られる抽出物を言う。 The Ogon extract in the present invention refers to an extract obtained by extraction from the roots of Scutellaria baicalensis Georgi, which is a kind of plant belonging to the genus Lamiaceae.
本発明におけるユーカリ抽出物とは、ユーカリから抽出されて得られる抽出物を言う。ユーカリとはフトモモ科ユーカリ属の植物の総称であり、そのような植物としては、例えば、ユーカリ・グロブラス（Ｅｕｃａｌｙｐｔｕｓ ｇｌｏｂｕｌｕｓ、別名：ユーカリノキ）、ユーカリ・シトリオドラ（Ｅｕｃａｌｙｐｔｕｓ Ｃｉｔｒｉｏｄｏｒａ、別名：レモンユーカリ）等がある。中でもユーカリ・グロブラスが好ましい。抽出には全草、またはその地上部、茎や葉等地上部の各部位を使用してもよいが、葉を使用することが好ましい。 The eucalyptus extract in the present invention refers to an extract obtained by extraction from eucalyptus. Eucalyptus is a general term for plants belonging to the genus Eucalyptus, and examples of such plants include Eucalyptus globulus (aka Eucalyptus), Eucalyptus Citriodora (aka Lemon Eucalyptus) and the like. . Of these, eucalyptus and globulas are preferred. For the extraction, the whole plant or each part of the above-ground part such as the above-ground part, stem and leaf may be used, but it is preferable to use the leaf.
本発明における上記植物抽出物としては、従来の抽出方法により抽出したものを用いてもよいし、市販のものを用いてもよい。
抽出方法としては例えば、適当な溶媒を用いて抽出する方法が挙げられる。
抽出の際は、使用する植物をそのまま用いてもよいし、粉砕や乾燥等を施して用いてもよいが、粉砕して用いることが好ましく、乾燥させたものを用いることがより好ましい。
As said plant extract in this invention, what was extracted by the conventional extraction method may be used, and a commercially available thing may be used.
Examples of the extraction method include a method of extraction using an appropriate solvent.
At the time of extraction, the plant to be used may be used as it is, or may be used after being pulverized or dried, but is preferably used after being pulverized, and more preferably dried.
抽出に使用する溶媒に特に制限はなく、水、低級１価アルコール類（例えばメタノール、エタノール、プロパノール、ブタノール等）、多価アルコール類（例えばプロピレングリコール、ジプロピレングリコール、ブチレングリコール、グリセリン等）、エステル類（例えば酢酸メチル、酢酸エチル等）、ケトン類（例えばアセトン、メチルエチルケトン等）、エーテル類（ジエチルエーテル、テトラヒドロフラン等）等の極性溶媒や、ハロゲン化炭化水素類（例えばクロロホルム、四塩化炭素等）、炭化水素類（例えばヘキサン、ヘプタン、シクロヘキサン等）等を用いることができる。またこれらのうちの１種を単独で用いても、２種以上からなる混合溶媒を用いてもよい。特に、極性溶媒を用いることが好ましい。 There is no particular limitation on the solvent used for extraction, water, lower monohydric alcohols (eg, methanol, ethanol, propanol, butanol, etc.), polyhydric alcohols (eg, propylene glycol, dipropylene glycol, butylene glycol, glycerin, etc.), Polar solvents such as esters (such as methyl acetate and ethyl acetate), ketones (such as acetone and methyl ethyl ketone), ethers (such as diethyl ether and tetrahydrofuran), and halogenated hydrocarbons (such as chloroform and carbon tetrachloride) ), Hydrocarbons (eg, hexane, heptane, cyclohexane, etc.) and the like can be used. One of these may be used alone, or a mixed solvent composed of two or more may be used. In particular, it is preferable to use a polar solvent.
抽出手順に特に制限はなく、例えば、抽出に使用する植物を２０〜４０℃の前記溶媒中に１時間〜７日間浸漬し、濾過する手順が挙げられる。
また、得られた抽出液を希釈、濃縮、凍結乾燥、精製等することにより抽出液の希釈液や濃縮液、乾燥物、精製物を得、これらを本発明に係る植物抽出物として用いることもできる。
There is no restriction | limiting in particular in an extraction procedure, For example, the procedure which immerses the plant used for extraction in the said solvent of 20-40 degreeC for 1 hour-7 days, and filters is mentioned.
In addition, by diluting, concentrating, lyophilizing, purifying, etc. the obtained extract, a diluted solution, concentrated solution, dried product, or purified product of the extract solution can be obtained, and these can be used as the plant extract according to the present invention. it can.
本発明においては、上記植物抽出物をそのまま本発明のＰＧＤ2産生抑制剤としてもよいし、以下に示す他の成分をさらに含んでいてもよい。 In the present invention, the plant extract may be used as the PGD 2 production inhibitor of the present invention as it is, or may further contain other components shown below.
本発明のＰＧＤ2産生抑制剤における上記植物抽出物の総含有量は、例えば乾燥物の質量で０.０００００１〜１０質量％という量が挙げられる。総含有量が前記下限未満であると本発明の作用が得られない恐れがあり、前記上限を超えると含有量に見合った作用が得られない傾向があり、コスト的に不利である。 The total content of the plant extract in PGD 2 production inhibitor of the present invention, for example an amount of from 0.000001 to 10% by weight by weight of dry matter and the like. If the total content is less than the lower limit, the action of the present invention may not be obtained, and if it exceeds the upper limit, the action corresponding to the content tends to be not obtained, which is disadvantageous in terms of cost.
本発明のＰＧＤ2産生抑制剤に使用可能な他の成分としては、例えば賦形剤、増粘剤、溶剤、分散剤、溶解補助剤、緩衝剤、防腐剤、抗酸化剤、着色剤等が挙げられる。 Examples of other components that can be used in the PGD 2 production inhibitor of the present invention include excipients, thickeners, solvents, dispersants, solubilizers, buffers, preservatives, antioxidants, and colorants. Can be mentioned.
具体的には、乳糖、白糖等の賦形剤；天然ガム類、セルロース誘導体、アクリル酸重合体等の増粘剤；注射用水、アルコール、プロピレングリコール、マルクゴール、ゴマ油、トウモロコシ油等の溶剤；ポリオキシエチレンソルビタンモノオレアート、ポリオキシエチレン硬化ヒマシ油、ポリエチレングリコール等の分散剤；Ｄ−マンニトール、安息香酸ベンジル、エタノール等の溶解補助剤；リン酸塩、酢酸塩、炭酸塩等の緩衝剤；パラオキシ安息香酸エステル類、クロロブタノール、ベンジルアルコール等の防腐剤；亜流酸塩、アスコルビン酸等の抗酸化剤等が挙げられる。 Specifically, excipients such as lactose and sucrose; thickeners such as natural gums, cellulose derivatives, and acrylic acid polymers; solvents such as water for injection, alcohol, propylene glycol, markgol, sesame oil, and corn oil; Dispersing agents such as polyoxyethylene sorbitan monooleate, polyoxyethylene hydrogenated castor oil, polyethylene glycol; solubilizing agents such as D-mannitol, benzyl benzoate, ethanol; buffering agents such as phosphate, acetate, carbonate A preservative such as paraoxybenzoates, chlorobutanol and benzyl alcohol; and an antioxidant such as sulfite and ascorbic acid.
本発明のＰＧＤ2産生抑制剤は、医薬品、医薬部外品、薬用又は化粧用の製剤類をはじめとする各種の外用剤に配合することが可能であるが、その優れたＰＧＤ2産生抑制効果により優れた脱毛抑制作用及び整肌作用が得られるため、頭髪（頭皮）又は皮膚に適用する頭髪化粧料又は皮膚化粧料に配合することが好適である。 The PGD 2 production inhibitor of the present invention can be blended in various external preparations including pharmaceuticals, quasi drugs, medicinal or cosmetic preparations, and has an excellent PGD 2 production inhibitory effect. Therefore, it is preferable to blend in hair cosmetics or skin cosmetics to be applied to the hair (scalp) or skin.
本発明の頭髪化粧料及び皮膚化粧料は、上記本発明のＰＧＤ2産生抑制剤と５α−リダクターゼ活性阻害剤とを含有するものである。上記本発明のＰＧＤ2産生抑制剤と５α−リダクターゼ活性阻害剤とを併用することにより、脱毛抑制作用及び整肌作用の向上効果が非常に優れたものとなる。 The hair cosmetics and skin cosmetics of the present invention contain the PGD 2 production inhibitor of the present invention and a 5α-reductase activity inhibitor. By using the PGD 2 production inhibitor of the present invention and the 5α-reductase activity inhibitor in combination, the effect of improving the hair loss inhibiting action and the skin conditioning action becomes very excellent.
５α−リダクターゼ活性阻害剤としては従来公知のものを特に制限なく使用することができ、例えば、ザクロ抽出物、チョウジ抽出物、グアバ抽出物、オトギリソウ抽出物、セージ抽出物、センキュウ抽出物、ハッカ抽出物、セイヨウハッカ抽出物、カミツレ抽出物、アルニカ抽出物等の植物抽出物を含有するものが挙げられる。 As the 5α-reductase activity inhibitor, conventionally known ones can be used without particular limitation. For example, pomegranate extract, clove extract, guava extract, hypericum extract, sage extract, sensu extract, mint extract And those containing plant extracts such as mint extract, chamomile extract, arnica extract.
中でも、脱毛抑制作用及び整肌作用の向上がより優れるという観点から、５α−リダクターゼ活性阻害剤としてはザクロ抽出物、チョウジ抽出物、グアバ抽出物、オトギリソウ抽出物、セージ抽出物からなる群より選ばれる少なくとも１種の植物抽出物を含有するものが好ましく、ザクロ抽出物、チョウジ抽出物及びグアバ抽出物の１種または２種以上を含有するものがより好ましい。 Among them, from the viewpoint of better hair loss inhibiting action and skin conditioning action, the 5α-reductase activity inhibitor is selected from the group consisting of pomegranate extract, clove extract, guava extract, hypericum extract, and sage extract In particular, those containing at least one plant extract are preferred, and those containing one or more of pomegranate extract, clove extract and guava extract are more preferred.
上記ザクロ抽出物とは、ザクロ科ザクロ属ザクロ（Ｐｕｎｉｃａ ｇｒａｎａｔｕｍ）から抽出されて得られる抽出物を言う。抽出には、全草、または果実、果皮、樹皮等の地上部の各部位を使用してもよいが、中でも果皮を使用することが好ましい。また、生薬の「柘榴皮」を用いてもよい。 The pomegranate extract refers to an extract obtained by extraction from a pomegranate family, Punica granatum. For extraction, the whole plant or each part of the above-ground part such as fruit, pericarp and bark may be used, but among these, pericarp is preferred. Alternatively, a herbal “skin” may be used.
上記チョウジ抽出物とは、フトモモ科フトモモ属チョウジノキ（Ｅｕｇｅｎｉａ ｃａｒｙｏｐｈｙｌｌｕｓ）から抽出されて得られる抽出物を言う。抽出には、全草、または葉、花、蕾、茎等地上部の各部位を使用してもよいが、中でも蕾を使用することが好ましい。また、同属植物を用いることができ、例えばフトモモ（Ｓｙｚｙｇｉｕｍ ｊａｍｂｏｓ）等が挙げられる。 The above-mentioned clove extract refers to an extract obtained by extraction from Eugenia caryophyllus. For the extraction, the whole plant or each part of the above-ground part such as leaves, flowers, buds and stems may be used. In addition, plants belonging to the same genus can be used, and examples thereof include yellow peach (Syzygium jambos).
上記グアバ抽出物とは、フトモモ科バンジロウ属グアバ（Ｐｓｉｄｉｕｍ ｇｕａｊａｖａ）から抽出されて得られる抽出物を言う。抽出には、全草、または葉、花、茎等の地上部の各部位を使用してもよいが、中でも葉を使用することが好ましい。 The guava extract refers to an extract obtained by extraction from Psidium guajava. For extraction, the whole plant or each part of the above-ground part such as a leaf, a flower, and a stem may be used, but it is preferable to use a leaf among them.
上記オトギリソウ抽出物とは、オトギリソウ科オトギリソウ属オトギリソウ（Ｈｙｐｅｒｉｃｕｍ ｅｒｅｃｔｕｍ）から抽出されて得られる抽出物を言う。抽出には、全草、または葉、花、茎等の地上部の各部位を使用してもよいが、中でも地上部を使用することが好ましい。 The above-mentioned Hypericum extract refers to an extract obtained by extraction from Hypericum electum. For the extraction, the whole plant or each part of the above-ground part such as a leaf, a flower, and a stem may be used, but it is preferable to use the above-ground part.
上記セージ抽出物とは、シソ科アオギリ属セージ（Ｓａｌｖｉａ ｏｆｆｉｃｉｎａｌｉｓ）から抽出されて得られる抽出物を言う。抽出には、全草、または葉、花、茎等の地上部の各部位を使用してもよいが、中でも全草または葉を使用することが好ましい。 The above sage extract refers to an extract obtained by extraction from a sage family Salvia officinalis. For the extraction, the whole grass or each part of the above-ground part such as a leaf, a flower, and a stem may be used, but it is particularly preferable to use the whole grass or the leaf.
上記植物抽出物としては、例えば上述の方法で抽出したものを用いてもよいし、市販のものを用いてもよい。また、得られた抽出液の希釈液や濃縮液、乾燥物、精製物を用いてもよい。 As said plant extract, what was extracted by the above-mentioned method may be used, for example, and a commercially available thing may be used. Moreover, you may use the dilution liquid of the obtained extract, a concentrated liquid, a dried product, and a purified product.
本発明の頭髪化粧料又は皮膚化粧料における、ＰＧＤ2産生抑制剤と５α−リダクターゼ活性阻害剤との質量比は、脱毛抑制作用及び整肌作用の向上がより優れるという観点から、植物抽出物の乾燥物の質量で５：９５〜６０：４０が好ましい。 The mass ratio of the PGD 2 production inhibitor and the 5α-reductase activity inhibitor in the hair cosmetic composition or skin cosmetic composition of the present invention is such that the plant hair extract is more excellent in hair loss inhibiting action and skin conditioning action. 5: 95-60: 40 is preferable by the mass of a dried material.
本発明の頭髪化粧料又は皮膚化粧料における上記本発明のＰＧＤ2産生抑制剤及び５α−リダクターゼ活性阻害剤の各含有量は、頭髪化粧料又は皮膚化粧料の剤型によって適宜調節され得るが、例えば植物抽出物の乾燥物の質量でそれぞれ０.０００００１〜１０質量％という量が挙げられる。各含有量が前記下限未満であると本発明の作用が得られない恐れがあり、前記上限を超えると含有量に見合った作用が得られない傾向があり、コスト的に不利である。 The contents of the PGD 2 production inhibitor and the 5α-reductase activity inhibitor of the present invention in the hair cosmetic or skin cosmetic of the present invention can be appropriately adjusted depending on the form of the hair cosmetic or skin cosmetic, For example, the quantity of 0.000001-10 mass% is mentioned by the mass of the dried material of a plant extract, respectively. If each content is less than the lower limit, the action of the present invention may not be obtained, and if it exceeds the upper limit, an action corresponding to the content tends to be not obtained, which is disadvantageous in terms of cost.
本発明の頭髪用化粧料としては、例えば、整髪料、ヘアトニック等の頭皮用化粧料、洗髪料、ヘアリンス、養毛剤、育毛剤等が挙げられ、また、皮膚用化粧料としては、例えば、化粧水、乳液、ボディローション、ボディクリーム、パック、軟膏、ファンデーション等が挙げられる。 Examples of the cosmetics for hair of the present invention include, for example, cosmetics for scalp such as hair styling and hair tonics, hair shampoos, hair rinses, hair nourishing agents, hair restorers and the like. Examples of skin cosmetics include cosmetics. Water, emulsion, body lotion, body cream, pack, ointment, foundation and the like can be mentioned.
本発明の頭髪化粧料及び皮膚化粧料には、本発明の効果を損なわない範囲で、頭髪化粧料及び皮膚化粧料に従来から使用される成分を配合することもできる。そのような成分としては例えば、保湿剤、エモリエント剤、血行促進剤、細胞賦活化剤、抗酸化剤、抗炎症剤、抗菌剤、過酸化物抑制剤、育毛、養毛効果を有する成分、上記以外の植物や動物、微生物由来の各種抽出物等が挙げられる。 In the hair cosmetic composition and skin cosmetic composition of the present invention, ingredients conventionally used in the hair cosmetic composition and skin cosmetic composition can be blended within a range not impairing the effects of the present invention. Such components include, for example, moisturizers, emollients, blood circulation promoters, cell activators, antioxidants, anti-inflammatory agents, antibacterial agents, peroxide inhibitors, hair growth, hair restoration effects, the above And various extracts derived from plants, animals, and microorganisms.
より具体的にはグリセリン、尿素、アミノ酸、ヒアルロン酸類等の保湿剤；スクワラン、マカデミアナッツ油、オリーブ油、ホホバ油、シリコン油等のエモリエント剤；ビタミンＥ類、トウガラシチンキ等の血行促進剤；核酸等の細胞賦活化剤、ジブチルヒドロキシ
トルエン（ＢＨＴ）、ジブチルヒドロキシアニソール（ＢＨＡ）、酢酸トコフェロール等の抗酸化剤；グリチルリチン、アラントイン等の抗炎症剤；ヒノキチオール、塩化ベンザルコニウム、クロルヘキシジン塩、パラヒドロキシ安息香酸エステル等の抗菌剤；スーパーオキシドジスムターゼ（ＳＯＤ）等の過酸化物抑制剤；チンピ、アロエ、ショウキョウ、ソウハクヒ等の生薬及びこれらの抽出物やパントテニルエチルエーテル、酢酸トコフェロール、フォルスコリン等の化合物等の育毛、養毛効果を有する成分；イチョウエキス、胎盤抽出物、乳酸菌培養抽出物等の上記以外の植物、動物、微生物由来の各種抽出物等が挙げられる。
More specifically, humectants such as glycerin, urea, amino acids and hyaluronic acids; emollients such as squalane, macadamia nut oil, olive oil, jojoba oil, and silicone oil; blood circulation promoters such as vitamin E and red pepper tincture; Cell activating agents, dibutylhydroxytoluene (BHT), dibutylhydroxyanisole (BHA), antioxidants such as tocopherol acetate; anti-inflammatory agents such as glycyrrhizin, allantoin; hinokitiol, benzalkonium chloride, chlorhexidine salt, parahydroxybenzoic acid Antibacterial agents such as esters; Peroxide inhibitors such as superoxide dismutase (SOD); Herbal medicines such as chimpi, aloe, ginger, sohakhi, etc., and extracts thereof, pantothenyl ethyl ether, tocopherol acetate, forskolin, etc. Hair growth, such as goods, components having a hair revitalizing effect, ginkgo extract, placenta extract, the other plants such as lactic acid bacteria culture extracts, animal, various extracts, etc. derived from microorganisms can be mentioned.
また、本発明の頭髪化粧料及び皮膚化粧料には、本発明の効果を損なわない範囲で、その剤型化のために界面活性剤、油脂類等の基材成分や、必要に応じて増粘剤、防腐剤、等張化剤、酸化防止剤、紫外線吸収剤、キレート剤、香料、着色料等の種々の添加物を併用することができる。 In addition, the hair cosmetics and skin cosmetics of the present invention may be added to base ingredients such as surfactants and fats and oils as needed for formulation, within the range that does not impair the effects of the present invention. Various additives such as a sticking agent, an antiseptic, an isotonic agent, an antioxidant, an ultraviolet absorber, a chelating agent, a fragrance, and a coloring agent can be used in combination.
以下、本発明を更に詳しく説明するために実施例によって説明するが、本発明はこれらの実施例により何ら限定されるものではない。
（１）製造方法
（１−１）ＰＧＤ2産生抑制剤
Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples.
(1) Production method (1-1) PGD 2 production inhibitor
（実施例１）
ローズマリーの葉を５０ｇ採取し、３７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しローズマリー抽出物３.１ｇを得た。これをＰＧＤ2産生抑制剤とした。
Example 1
50 g of rosemary leaves were collected and immersed in 375 ml of 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 3.1 g of a rosemary extract. This was used as a PGD 2 production inhibitor.
（実施例２）
タチジャコウソウの花、葉、茎を５０ｇ採取し、３７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しタイム抽出物９.０ｇを得た。これをＰＧＤ2産生抑制剤とした。
(Example 2)
50 g of flowers, leaves and stems were collected and immersed in 375 ml of a 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by freeze-drying to obtain 9.0 g of a thyme extract. This was used as a PGD 2 production inhibitor.
（実施例３）
カワラヨモギの花を５０ｇ採取し、３７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しカワラヨモギ抽出物９.３ｇを得た。これをＰＧＤ2産生抑制剤とした。
Example 3
50 g of Kawara mugwort flowers were collected and immersed in 375 ml of 50% by mass aqueous ethanol at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 9.3 g of the extract of Kawamomogi. This was used as a PGD 2 production inhibitor.
（実施例４）
コガネバナの根を５０ｇ採取し、３７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しオウゴン抽出物１４.１ｇを得た。これをＰＧＤ2産生抑制剤とした。
Example 4
50 g of roots of Koganebana were collected and immersed in 375 ml of 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 14.1 g of an orgone extract. This was used as a PGD 2 production inhibitor.
（実施例５）
ユーカリの葉を５０ｇ採取し、３７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しユーカリ抽出物１１.１ｇを得た。これをＰＧＤ2産生抑制剤とした。
(Example 5)
50 g of eucalyptus leaves were collected and immersed in 375 ml of a 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 11.1 g of an eucalyptus extract. This was used as a PGD 2 production inhibitor.
（１−２）５α−リダクターゼ活性阻害剤
（製造例１）
ザクロの果皮を５０ｇ採取し、２７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しザクロ抽出物１４.７ｇを得た。これを５α−リダクターゼ活性阻害剤とした。
(1-2) 5α-reductase activity inhibitor (Production Example 1)
50 g of pomegranate peels were collected and immersed in 275 ml of a 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 14.7 g of a pomegranate extract. This was used as a 5α-reductase activity inhibitor.
（製造例２）
チョウジの花蕾を５０ｇ採取し、２７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しチョウジエキス９.３ｇを得た。これを５α−リダクターゼ活性阻害剤とした。
(Production Example 2)
50 g of clove flower buds were collected and immersed in 275 ml of 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 9.3 g of clove extract. This was used as a 5α-reductase activity inhibitor.
（製造例３）
グアバの葉を５０ｇ採取し、２７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しグアバ抽出物７.４ｇを得た。これを５α−リダクターゼ活性阻害剤とした。
(Production Example 3)
50 g of guava leaves were collected and immersed in 275 ml of a 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 7.4 g of guava extract. This was used as a 5α-reductase activity inhibitor.
（製造例４）
オトギリソウの地上部を５０ｇ採取し、２７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しオトギリソウ抽出物４.５ｇを得た。これを５α−リダクターゼ活性阻害剤とした。
(Production Example 4)
50 g of the above-ground part of hypericum was collected and immersed in 275 ml of a 50% by mass aqueous ethanol solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by freeze-drying to obtain 4.5 g of Hypericum extract. This was used as a 5α-reductase activity inhibitor.
（製造例５）
セージの全草を５０ｇ採取し、２７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しセージ抽出物１０.３ｇを得た。これを５α−リダクターゼ活性阻害剤とした。
(Production Example 5)
50 g of whole sage grass was collected and immersed in 275 ml of 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 10.3 g of a sage extract. This was used as a 5α-reductase activity inhibitor.
（製造例６）
センキュウの根茎を５０ｇ採取し、２７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しセンキュウ抽出物１６.２ｇを得た。これを５α−リダクターゼ活性阻害剤とした。
(Production Example 6)
50 g of rhizome of senkyu were collected and immersed in 275 ml of a 50% by mass aqueous ethanol solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 16.2 g of a Senkyu extract. This was used as a 5α-reductase activity inhibitor.
（１−３）比較成分
（比較例１）
シナモンの樹皮を５０ｇ採取し、２７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しシナモン抽出物９.５ｇを得た。これを比較成分とした。
(1-3) Comparative component (Comparative Example 1)
50 g of cinnamon bark was collected and immersed in 275 ml of a 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 9.5 g of a cinnamon extract. This was used as a comparative component.
（比較例２）
チャノキの葉を５０ｇ採取し、２７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃）下で浸漬した。２４時間後これをろ過し、得られた抽出液から水、エタノールを減圧留去後、凍結乾燥しチャノキ抽出物６.３ｇを得た。これを比較成分とした。
(Comparative Example 2)
50 g of chanoki leaves were collected and immersed in 275 ml of 50% by mass ethanol aqueous solution at room temperature (about 25 ° C.). After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 6.3 g of a chanoki extract. This was used as a comparative component.
（比較例３）
ユリの根を５０ｇ採取し、２７５ｍｌの５０質量％エタノール水溶液に室温（約２５℃
）下で浸漬した。２４時間後これをろ過し、得られた抽出物から水、エタノールを減圧留去後、凍結乾燥し抽出物８.７ｇを得た。これを比較成分とした。
(Comparative Example 3)
50 g of lily roots were collected and placed in 275 ml of 50% by weight ethanol aqueous solution at room temperature (about 25 ° C.
) Dipped under. After 24 hours, this was filtered, and water and ethanol were distilled off from the resulting extract under reduced pressure, followed by lyophilization to obtain 8.7 g of the extract. This was used as a comparative component.
（２）ＰＧＤ2産生抑制剤
（２−１）ＰＧＤ2産生抑制率試験
細胞はラット由来マスト細胞（ＲＢＬ−２Ｈ３細胞）を使用した。サブコンフルエント状態のＲＢＬ−２Ｈ３細胞をトリプシン処理で剥離し、４８ウェルプレートの各ウェルに８０，０００ｃｅｌｌｓずつ播種し、１０％胎仔ウシ血清（以下、ＦＢＳとする）含有ダルベッコ改変イーグル培地（以下、ＤＭＥＭとする）で２４時間、３７℃、５％ＣＯ2条件下で培養した。実施例１〜５のＰＧＤ2産生抑制剤、比較例１及び比較例２の比較成分をそれぞれジメチルスルホキシド（以下、ＤＭＳＯとする）に溶解させたものを用いて、ＰＧＤ2産生抑制剤又は比較成分濃度が表１に記載の濃度でありＤＭＳＯ濃度が０.１質量％である０.５％ＦＢＳ含有ＤＭＥＭに培地を調整し、培地をこれに交換し、１時間培養した。その後、ＰＧＤ2産生促進剤として、Ａ２３１８７（カルシウムイオノフォア）を０.５μＭとなるように添加し、３０分後に培養上清を回収した。
(2) PGD 2 production inhibitor (2-1) PGD 2 production inhibition rate test Rat-derived mast cells (RBL-2H3 cells) were used as the cells. Subconfluent RBL-2H3 cells are detached by trypsin treatment, seeded with 80,000 cells in each well of a 48-well plate, and Dulbecco's modified Eagle's medium (hereinafter DMEM) containing 10% fetal calf serum (hereinafter referred to as FBS). And 24 hours at 37 ° C. and 5% CO 2 . The PGD 2 production inhibitor of Examples 1 to 5, the comparative component of Comparative Examples 1 and 2 were dissolved in dimethyl sulfoxide (hereinafter referred to as DMSO), and the PGD 2 production inhibitor or comparative component was used. The medium was adjusted to 0.5% FBS-containing DMEM having a concentration shown in Table 1 and a DMSO concentration of 0.1% by mass, and the medium was changed to this and cultured for 1 hour. Thereafter, A23187 (calcium ionophore) was added as a PGD 2 production promoter to a concentration of 0.5 μM, and the culture supernatant was recovered after 30 minutes.
また、ＰＧＤ2産生抑制剤、比較成分をＤＭＳＯに溶解させたものの代わりにＤＭＳＯ水溶液を用いたこと以外は上述と同様の方法で培養したものを陰性対照とした。
回収した培養上清に含まれるＰＧＤ2の定量には、「ＰＧＤ２−ＭＯＸ ＥＩＡ ｋｉｔｓ」（Ｃａｙｍａｎ Ｃｈｅｍｉｃａｌ社）を使用し、ＥＬＩＳＡ法により測定した。ＰＧＤ2産生抑制率は、陰性対照に対しての抑制率を計算した。計算式は下記の通りである。この結果を表１に示す。
ＰＧＤ2産生抑制率（％）＝（１−Ｙ／Ｘ）×１００
Ｘ：陰性対照のＰＧＤ2量
Ｙ：ＰＧＤ2産生抑制剤又は比較成分添加時のＰＧＤ2量
A negative control was prepared by culturing in the same manner as described above except that an aqueous solution of DMSO was used instead of the PGD 2 production inhibitor and the comparative component dissolved in DMSO.
For the quantification of PGD 2 contained in the collected culture supernatant, “PGD2-MOX EIA kits” (Cayman Chemical Co.) was used and measured by ELISA. For the PGD 2 production inhibition rate, the inhibition rate relative to the negative control was calculated. The calculation formula is as follows. The results are shown in Table 1.
PGD 2 production inhibition rate (%) = (1−Y / X) × 100
X: PGD 2 amount of negative control Y: PGD 2 production inhibitor or PGD 2 amount when compared components added
（２−２）脱毛抑制作用試験
実施例１〜５のＰＧＤ2産生抑制剤及び比較例１の比較成分を用いて、試験用頭髪化粧料として、ヘアトニック、シャンプー及びコンディショナーを以下の組成で調整した。なお、配合量の単位は質量部で、精製水の「残量」とは全量を１００質量部とする量である。また、シャンプーにおける、クエン酸２５質量％水溶液の適量とはｐＨを約５.５に調整するのに要する量、塩化ナトリウム１０質量％水溶液の適量とは粘度を約１５００ｍＰａ・sに調整するのに要する量である。
(2-2) Hair loss inhibitory action test Using the PGD 2 production inhibitor of Examples 1 to 5 and the comparative component of Comparative Example 1, hair tonic, shampoo and conditioner were prepared with the following composition as test hair cosmetics. did. The unit of the blending amount is parts by mass, and the “remaining amount” of purified water is an amount that makes the total amount 100 parts by mass. In addition, the appropriate amount of 25% by weight citric acid aqueous solution in shampoo is the amount required to adjust the pH to about 5.5, and the proper amount of 10% sodium chloride aqueous solution is to adjust the viscosity to about 1500 mPa · s. It is a necessary amount.
ヘアトニックの試験を被験者５名で行い、シャンプー及びコンディショナーの試験を被験者５名で行った。被験者は３０〜５０歳のＡＧＡを発症している男性とした。
３ヶ月間の試験中、ヘアトニックの試験については毎日の入浴後及び朝に頭皮に適量使用してもらい、シャンプー及びコンディショナーの試験については、毎日の入浴時に頭髪に適量使用してもらった。
A hair tonic test was conducted with 5 subjects, and a shampoo and conditioner test was conducted with 5 subjects. The test subject was a male who developed AGA 30 to 50 years old.
During the 3-month study, the hair tonic test was used on the scalp after daily bathing and in the morning, and the shampoo and conditioner test was used on the hair at the daily bathing time.
試験開始前と終了後の３日において、１日１回の洗髪時の抜け毛数を数えた。１日当たりの抜け毛数を３日分の抜け毛数の平均値として算出し、試験開始前の平均抜け毛数に対する終了後の平均抜け毛数の減少率を算出し、下記の評価点基準に従って点数をつけた。次に、各試験の被験者５名の評価点を合計し、以下の判定基準により判定した。その結果を表１に示す。
なお、試験中に皮膚の異常を訴えた者はいなかった。
Three days before and after the start of the test, the number of hair loss at the time of washing once a day was counted. The number of hair loss per day was calculated as the average value of the number of hair loss for 3 days, the reduction rate of the average number of hair loss after the end relative to the average number of hair loss before the start of the test was calculated, and the score was given according to the following evaluation point criteria . Next, the evaluation points of five test subjects in each test were summed up and determined according to the following criteria. The results are shown in Table 1.
No one complained of skin abnormalities during the study.
（ｉ）ヘアトニック
エタノール ４０
オレイン酸エチル １
ポリオキシエチレン（４０モル）硬化ヒマシ油 ２
メチルパラベン ０.２
精製水 残量
ＰＧＤ2産生抑制剤又は比較成分 ０.０１
合計 １００
（ii）シャンプー
ポリクオタニウム−７ ０.０５
ラウリル硫酸ナトリウム １０
ポリオキシエチレン（３モル）ラウリル硫酸ナトリウム １０
コカミドプロピルベタイン ３
コカミドジエタノールアミド １
精製水 残量
クエン酸２５％水溶液 適量
塩化ナトリウム１０％水溶液 適量
エタノール １０
プロピレングリコール ３
メチルパラベン ０.２
ＰＧＤ2産生抑制剤又は比較成分 ０.０１
合計 １００
（iii）コンディショナー
メチルポリシロキサン ３
セタノール ４
ポリオキシエチレン（４０モル）モノステアレート ０.３
ベヘニルトリメチルアンモニウムクロリド ２.５
カチオン化グァーガム ０.４
パンテニルヒドロキシプロピルステアルジモニウムクロリド ０.３
メチルパラベン ０.２
精製水 残量
水酸化ナトリウム１０％水溶液 ０.２
エタノール １０
プロピレングリコール ３
ＰＧＤ2産生抑制剤又は比較成分 ０.０１
合計 １００
(I) Hair tonic ethanol 40
Ethyl oleate 1
Polyoxyethylene (40 mol) hydrogenated castor oil 2
Methylparaben 0.2
Purified water remaining amount PGD 2 production inhibitor or comparative component 0.01
Total 100
(Ii) Shampoo Polyquaternium-7 0.05
Sodium lauryl sulfate 10
Polyoxyethylene (3 mol) sodium lauryl sulfate 10
Cocamidopropyl betaine 3
Cocamide diethanolamide 1
Purified water Remaining 25% aqueous solution of citric acid Appropriate amount 10% aqueous solution of sodium chloride Appropriate amount Ethanol 10
Propylene glycol 3
Methylparaben 0.2
PGD 2 production inhibitor or comparative component 0.01
Total 100
(Iii) Conditioner Methylpolysiloxane 3
Cetanol 4
Polyoxyethylene (40 mol) monostearate 0.3
Behenyltrimethylammonium chloride 2.5
Cationized guar gum 0.4
Panthenyl hydroxypropyl stearidimonium chloride 0.3
Methylparaben 0.2
Purified water Residual amount Sodium hydroxide 10% aqueous solution 0.2
Ethanol 10
Propylene glycol 3
PGD 2 production inhibitor or comparative component 0.01
Total 100
（評価点基準）
１０点：４０％以上の減少
８点 ：３０％以上から４０％未満の減少
６点 ：２０％以上から３０％未満の減少
４点 ：１０％以上から２０％未満の減少
２点 ：５％以上から１０％未満の減少
０点 ：５％未満の減少
（判定基準）
１級 ：評価点の合計が ４６〜５０点
２級 ：評価点の合計が ４１〜４５点
３級 ：評価点の合計が ３６〜４０点
４級 ：評価点の合計が ３１〜３５点
５級 ：評価点の合計が ２６〜３０点
６級 ：評価点の合計が ２１〜２５点
７級 ：評価点の合計が １６〜２０点
８級 ：評価点の合計が １１〜１５点
９級 ：評価点の合計が ６〜１１点
１０級：評価点の合計が ５点以下
(Evaluation criteria)
10 points: Reduction of 40% or more 8 points: Reduction of 30% or more to less than 40% 6 points: Reduction of 20% or more to less than 30% 4 points: Reduction of 10% or more to less than 20% 2 points: 5% or more Reduction of less than 10% from 0 point: Reduction of less than 5%
1st grade: Total evaluation points 46-50 points 2nd grade: total evaluation points 41-45 points 3rd grade: total evaluation points 36-40 points 4th grade: total evaluation points 31-35 points 5th grade : Total evaluation points 26-30 points 6 grades: Total evaluation points 21-25 points 7 grades: Total evaluation points 16-20 points 8 grades: Total evaluation points 11-15 points 9 grades: Evaluation The total score is 6-11 points, 10th grade: the total score is 5 points or less
（２−３）整肌作用試験
実施例１〜５のＰＧＤ2産生抑制剤及び比較例２の比較成分を用いて、試験用皮膚化粧料として化粧水及び乳液を以下の組成で調整した。なお、配合量の単位は質量部で、精製水の「残量」とは全量を１００質量部とする量である。
化粧水及び乳液の試験を、２５〜５０歳の肌荒れを呈する被験者１０名（男女各５名）で行った。
(2-3) Skin conditioning effect test Using the PGD 2 production inhibitor of Examples 1 to 5 and the comparative component of Comparative Example 2, skin lotions and emulsions were prepared as test skin cosmetics with the following composition. The unit of the blending amount is parts by mass, and the “remaining amount” of purified water is an amount that makes the total amount 100 parts by mass.
The test of lotion and milky lotion was conducted with 10 subjects (5 men and women) who had rough skin of 25 to 50 years old.
１ヶ月の試験中、被験者に化粧水及び乳液を毎日、朝晩の洗顔後に顔に適量使用してもらい、試験開始前と終了後に被験者の肌を目視及び触感により観察し、開始前と比べ肌荒れが改善した人数を数えた。その結果を表１に示す。
なお、試験中に皮膚の異常を訴えた者はいなかった。
During the 1-month test, subjects were asked to use lotion and milk lotion every day, after morning and evening face washing, and the skin of the subject was visually and tactilely observed before and after the test. The number of people who improved was counted. The results are shown in Table 1.
No one complained of skin abnormalities during the study.
（ｉ）化粧水
１，３−ブチレングリコール １
グリセリン ２
ペンチレングリコール １
メチルパラベン ０.２
精製水 残量
ＰＧＤ2産生抑制剤又は比較成分 ０.０１
合計 １００
（ii）乳液
メチルポリシロキサン ３
セタノール ５
ステアリン酸 ３
ワセリン ５
１，３−ブチレングリコール １０
グリセリン ５
メチルパラベン ０.２
精製水 残量
ＰＧＤ2産生抑制剤又は比較成分 ０.０１
合計 １００
(I) Lotion 1,3-butylene glycol 1
Glycerin 2
Pentylene glycol 1
Methylparaben 0.2
Purified water remaining amount PGD 2 production inhibitor or comparative component 0.01
Total 100
(Ii) Latex Methylpolysiloxane 3
Cetanol 5
Stearic acid 3
Vaseline 5
1,3-butylene glycol 10
Glycerin 5
Methylparaben 0.2
Purified water remaining amount PGD 2 production inhibitor or comparative component 0.01
Total 100
表１に示すように、本発明のＰＧＤ2産生抑制剤は優れたＰＧＤ2産生抑制効果を示した。
また、表１に示すように、本発明のＰＧＤ2産生抑制剤を用いた頭髪化粧料及び皮膚化粧料は、優れた脱毛抑制作用及び整肌作用を有する。
As shown in Table 1, the PGD 2 production inhibitor of the present invention showed an excellent PGD 2 production inhibitory effect.
Moreover, as shown in Table 1, the hair cosmetics and skin cosmetics using the PGD 2 production inhibitor of the present invention have an excellent hair loss inhibiting action and skin conditioning action.
（３）頭髪化粧料
実施例１〜５のＰＧＤ2産生抑制剤、製造例１〜６の５α−リダクターゼ活性阻害剤及び比較例１及び比較例３の比較成分を用いて、試験用頭髪化粧料としてヘアトニック（実施例６〜２３、比較例３〜１２）、シャンプー及びコンディショナー（実施例２４〜３０）を以下の組成で調整した。各頭髪化粧料におけるＰＧＤ2産生抑制剤、５α−リダクターゼ活性阻害剤及び比較成分の配合量を表２〜５に示す。なお、配合量の単位は質量部で、精製水の「残量」とは全量を１００質量部とする量である。また、シャンプーにおける、クエン酸２５質量％水溶液の適量とはｐＨを約５.５に調整するのに要する量、塩化ナトリウム１０質量％水溶液の適量とは粘度を約１５００ｍＰａ・sに調整するのに要する量である。
(3) Hair cosmetics Test hair cosmetics using the PGD 2 production inhibitors of Examples 1 to 5, the 5α-reductase activity inhibitors of Production Examples 1 to 6 and the comparative components of Comparative Examples 1 and 3. As a hair tonic (Examples 6 to 23, Comparative Examples 3 to 12), shampoos and conditioners (Examples 24 to 30) were prepared with the following compositions. Tables 2 to 5 show the amounts of the PGD 2 production inhibitor, the 5α-reductase activity inhibitor, and the comparative component in each hair cosmetic composition. The unit of the blending amount is parts by mass, and the “remaining amount” of purified water is an amount that makes the total amount 100 parts by mass. In addition, the appropriate amount of 25% by weight citric acid aqueous solution in shampoo is the amount required to adjust the pH to about 5.5, and the proper amount of 10% sodium chloride aqueous solution is to adjust the viscosity to about 1500 mPa · s. It is a necessary amount.
得られた頭髪化粧料の脱毛抑制作用試験を上記と同様にして行った。その結果を表２〜５に示す。なお、試験中に皮膚の異常を訴えた者はいなかった。
（ｉ）ヘアトニック
エタノール ４０
オレイン酸エチル １
ポリオキシエチレン（４０モル）硬化ヒマシ油 ２
メチルパラベン ０.２
精製水 残量
ＰＧＤ2産生抑制剤 表２〜４に記載の量
５α−リダクターゼ活性阻害剤 表２〜４に記載の量
比較成分 表２〜４に記載の量
合計 １００
（ii）シャンプー
ポリクオタニウム−７ ０.０５
ラウリル硫酸ナトリウム １０
ポリオキシエチレン（３モル）ラウリル硫酸ナトリウム １０
コカミドプロピルベタイン ３
コカミドジエタノールアミド １
精製水 残量
クエン酸２５質量％水溶液 適量
塩化ナトリウム１０質量％水溶液 適量
エタノール １０
プロピレングリコール ３
メチルパラベン ０.２
ＰＧＤ2産生抑制剤 表２〜４に記載の量
５α−リダクターゼ活性阻害剤 表２〜４に記載の量
比較成分 表２〜４に記載の量
合計 １００
(iii）コンディショナー
メチルポリシロキサン ３
セタノール ４
ポリオキシエチレン（４０モル）モノステアレート ０.３
ベヘニルトリメチルアンモニウムクロリド ２.５
カチオン化グァーガム ０.４
パンテニルヒドロキシプロピルステアルジモニウムクロリド ０.３
メチルパラベン ０.２
精製水 残量
水酸化ナトリウム１０質量％水溶液 ０.２
エタノール １０
プロピレングリコール ３
ＰＧＤ2産生抑制剤 表５に記載の量
５α−リダクターゼ活性阻害剤 表５に記載の量
比較成分 表５に記載の量
合計 １００
The hair loss inhibitory effect test of the obtained hair cosmetic was carried out in the same manner as described above. The results are shown in Tables 2-5. No one complained of skin abnormalities during the study.
(I) Hair tonic ethanol 40
Ethyl oleate 1
Polyoxyethylene (40 mol) hydrogenated castor oil 2
Methylparaben 0.2
Purified water remaining amount PGD 2 production inhibitor Amounts listed in Tables 2-4 5α-reductase activity inhibitors Amounts listed in Tables 2-4 Comparative components Amounts listed in Tables 2-4 Total 100
(Ii) Shampoo Polyquaternium-7 0.05
Sodium lauryl sulfate 10
Polyoxyethylene (3 mol) sodium lauryl sulfate 10
Cocamidopropyl betaine 3
Cocamide diethanolamide 1
Purified water Remaining amount 25% by weight citric acid aqueous solution Appropriate amount Sodium chloride 10% by weight aqueous solution Appropriate amount Ethanol 10
Propylene glycol 3
Methylparaben 0.2
PGD 2 production inhibitor Amounts listed in Tables 2-4 5α-reductase activity inhibitors Amounts listed in Tables 2-4 Comparative components Amounts listed in Tables 2-4 Total 100
(iii) Conditioner Methylpolysiloxane 3
Cetanol 4
Polyoxyethylene (40 mol) monostearate 0.3
Behenyltrimethylammonium chloride 2.5
Cationized guar gum 0.4
Panthenyl hydroxypropyl stearidimonium chloride 0.3
Methylparaben 0.2
Purified water remaining amount Sodium hydroxide 10 mass% aqueous solution 0.2
Ethanol 10
Propylene glycol 3
PGD 2 production inhibitor Amount described in Table 5 5α-reductase activity inhibitor Amount described in Table 5 Comparative component Amount described in Table 5 Total 100
表２〜５に示すように、本発明の頭髪化粧料は優れた脱毛抑制作用を有することが分かった。 As shown in Tables 2 to 5, it was found that the hair cosmetic composition of the present invention has an excellent hair loss inhibiting action.
（４）皮膚化粧料
実施例１〜５のＰＧＤ2産生抑制剤、製造例１〜６の５α−リダクターゼ活性阻害剤及び比較例１〜３の比較成分を用いて、試験用皮膚化粧料として、化粧水及び乳液（実施例３１〜４８、比較例１３〜２４）を以下の組成で調整した。各皮膚化粧料におけるＰＧＤ2産生抑制剤、５α−リダクターゼ活性阻害剤及び比較成分の配合量を表６〜８に示す。なお、配合量の単位は質量部で、精製水の「残量」とは全量を１００質量部とする量である。
(4) Skin cosmetics Using the PGD 2 production inhibitors of Examples 1 to 5, the 5α-reductase activity inhibitors of Production Examples 1 to 6 and the comparative components of Comparative Examples 1 to 3, as test skin cosmetics, A lotion and emulsion (Examples 31 to 48, Comparative Examples 13 to 24) were prepared with the following compositions. Tables 6 to 8 show the blending amounts of the PGD 2 production inhibitor, the 5α-reductase activity inhibitor and the comparative component in each skin cosmetic. The unit of the blending amount is parts by mass, and the “remaining amount” of purified water is an amount that makes the total amount 100 parts by mass.
得られた皮膚化粧料の整肌作用試験を上記と同様にして行った。その結果を表６〜８に示す。なお、試験中に皮膚の異常を訴えた者はいなかった。
（ｉ）化粧水
１，３−ブチレングリコール １
グリセリン ２
ペンチレングリコール １
メチルパラベン ０.２
精製水 残量
ＰＧＤ2産生抑制剤 表６〜８に記載の量
５α−リダクターゼ活性阻害剤 表６〜８に記載の量
比較成分 表６〜８に記載の量
合計 １００
（ii）乳液
メチルポリシロキサン ３
セタノール ５
ステアリン酸 ３
ワセリン ５
１，３−ブチレングリコール １０
グリセリン ５
メチルパラベン ０.２
精製水 残量
ＰＧＤ2産生抑制剤 表６〜８に記載の量
５α−リダクターゼ活性阻害剤 表６〜８に記載の量
比較成分 表６〜８に記載の量
合計 １００
The skin conditioning test of the obtained skin cosmetic was performed in the same manner as described above. The results are shown in Tables 6-8. No one complained of skin abnormalities during the study.
(I) Lotion 1,3-butylene glycol 1
Glycerin 2
Pentylene glycol 1
Methylparaben 0.2
Purified water remaining amount PGD 2 production inhibitor Amounts listed in Tables 6-8 5α-reductase activity inhibitors Amounts listed in Tables 6-8 Comparative components Amounts listed in Tables 6-8 Total 100
(Ii) Latex Methylpolysiloxane 3
Cetanol 5
Stearic acid 3
Vaseline 5
1,3-butylene glycol 10
Glycerin 5
Methylparaben 0.2
Purified water remaining amount PGD 2 production inhibitor Amounts listed in Tables 6-8 5α-reductase activity inhibitors Amounts listed in Tables 6-8 Comparative components Amounts listed in Tables 6-8 Total 100
本発明のＰＧＤ2産生抑制剤は、優れた脱毛抑制作用及び整肌作用を有しており、脱毛や薄毛、中でも特にＡＧＡ、肌荒れの予防や改善を目的とした化粧品をはじめとする各種外用剤への利用が可能となる。
また、本発明の頭髪化粧料及び皮膚化粧料は、優れた脱毛抑制作用及び整肌作用を有しており、脱毛や薄毛、中でも特にＡＧＡ、肌荒れの予防や改善を図ることができる。
The PGD 2 production inhibitor of the present invention has an excellent hair removal inhibitory action and skin conditioning action, and various external preparations including hair removal and thin hair, especially AGA, cosmetics for the purpose of preventing and improving rough skin. Can be used.
Moreover, the hair cosmetics and skin cosmetics of the present invention have excellent hair removal inhibiting action and skin conditioning action, and can prevent and improve hair loss and thin hair, especially AGA and rough skin.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013147341A JP6322368B2 (en) | 2013-07-16 | 2013-07-16 | Hair cosmetic and skin cosmetic containing PGD2 production inhibitor and 5α-reductase activity inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013147341A JP6322368B2 (en) | 2013-07-16 | 2013-07-16 | Hair cosmetic and skin cosmetic containing PGD2 production inhibitor and 5α-reductase activity inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015020949A true JP2015020949A (en) | 2015-02-02 |
| JP6322368B2 JP6322368B2 (en) | 2018-05-09 |
Family
ID=52485707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013147341A Active JP6322368B2 (en) | 2013-07-16 | 2013-07-16 | Hair cosmetic and skin cosmetic containing PGD2 production inhibitor and 5α-reductase activity inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6322368B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020090466A (en) * | 2018-12-07 | 2020-06-11 | 株式会社ナリス化粧品 | Epidermal cell TRPM8 activator |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60146829A (en) * | 1984-01-05 | 1985-08-02 | Rooto Seiyaku Kk | Testosterone 5alpha-reductase inhibitor |
| JPH0418026A (en) * | 1990-05-09 | 1992-01-22 | Noevir Co Ltd | Testosterone 5 alpha-reductase inhibitor |
| JP2002338439A (en) * | 2001-05-11 | 2002-11-27 | Personal Cosmedic Kk | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR AND HAIR-GROWING AGENT |
| JP2005053880A (en) * | 2003-08-07 | 2005-03-03 | Yasushi Kijima | Oily hair cleaning liquid preventing and ameliorating scalp trouble and method for hair cleaning treatment using the same |
| JP2005343825A (en) * | 2004-06-03 | 2005-12-15 | Noguchi Igaku Kenkyusho:Kk | Hair-growing agent |
| JP2007520545A (en) * | 2004-02-05 | 2007-07-26 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | Antiallergic compositions and related methods |
| WO2007089132A1 (en) * | 2006-02-03 | 2007-08-09 | Alanis Cabrera Francisco Javie | Improved method for the manufacture of soap for hair treatment and active ingredients for shampoos, lotions, gels and creams and resulting soap |
| JP2010013442A (en) * | 2008-06-04 | 2010-01-21 | Maruzen Pharmaceut Co Ltd | Hair growth regulating agent and skin cosmetic for hair growth regulation |
| JP2010163418A (en) * | 2008-12-18 | 2010-07-29 | Lion Corp | Cosmetic |
| US20120040030A1 (en) * | 2008-12-31 | 2012-02-16 | Bzmi, Llc | Herbal-based nasal solution and method of use thereof |
-
2013
- 2013-07-16 JP JP2013147341A patent/JP6322368B2/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60146829A (en) * | 1984-01-05 | 1985-08-02 | Rooto Seiyaku Kk | Testosterone 5alpha-reductase inhibitor |
| JPH0418026A (en) * | 1990-05-09 | 1992-01-22 | Noevir Co Ltd | Testosterone 5 alpha-reductase inhibitor |
| JP2002338439A (en) * | 2001-05-11 | 2002-11-27 | Personal Cosmedic Kk | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR AND HAIR-GROWING AGENT |
| JP2005053880A (en) * | 2003-08-07 | 2005-03-03 | Yasushi Kijima | Oily hair cleaning liquid preventing and ameliorating scalp trouble and method for hair cleaning treatment using the same |
| JP2007520545A (en) * | 2004-02-05 | 2007-07-26 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | Antiallergic compositions and related methods |
| JP2005343825A (en) * | 2004-06-03 | 2005-12-15 | Noguchi Igaku Kenkyusho:Kk | Hair-growing agent |
| WO2007089132A1 (en) * | 2006-02-03 | 2007-08-09 | Alanis Cabrera Francisco Javie | Improved method for the manufacture of soap for hair treatment and active ingredients for shampoos, lotions, gels and creams and resulting soap |
| JP2010013442A (en) * | 2008-06-04 | 2010-01-21 | Maruzen Pharmaceut Co Ltd | Hair growth regulating agent and skin cosmetic for hair growth regulation |
| JP2010163418A (en) * | 2008-12-18 | 2010-07-29 | Lion Corp | Cosmetic |
| US20120040030A1 (en) * | 2008-12-31 | 2012-02-16 | Bzmi, Llc | Herbal-based nasal solution and method of use thereof |
Non-Patent Citations (3)
| Title |
|---|
| MINTEL GNPD ID:10139418(2003年6月掲載), JPN7017002972, ISSN: 0003640871 * |
| MINTEL GNPD ID:792779(2007年10月掲載), JPN7017002970, ISSN: 0003640869 * |
| MINTEL GNPD ID:833183(2007年12月掲載), JPN7017002971, ISSN: 0003640870 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020090466A (en) * | 2018-12-07 | 2020-06-11 | 株式会社ナリス化粧品 | Epidermal cell TRPM8 activator |
| JP7190637B2 (en) | 2018-12-07 | 2022-12-16 | 株式会社ナリス化粧品 | Epidermal cell TRPM8 activator |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6322368B2 (en) | 2018-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110934783A (en) | Dandruff-removing and itching-relieving composition containing Chinese herbal medicines, silicone oil-free amino acid shampoo containing composition, and preparation method and application of silicone oil-free amino acid shampoo | |
| KR100960054B1 (en) | Hair cosmetic composition for improving stste of scalp and preventing fall-out of hair | |
| JPH0717847A (en) | Skin external preparation | |
| KR20100132511A (en) | Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method | |
| TWI636796B (en) | EXTERNAL COMPOSITION FOR SKIN CONTAINING GINSENOSIDE Rg3 | |
| JP2006241059A (en) | Skin cosmetic for pimple | |
| JPH0717845A (en) | Skin external preparation | |
| KR102175249B1 (en) | Composition for improving condition of hair and scalp containing Panax ginseng extract and Green tea extract | |
| WO2012081370A1 (en) | Inhibitor of activity of endothelin, and skin whitening agent | |
| JP4027949B2 (en) | Hair nourishing agent | |
| KR20200076101A (en) | Natural hair growth agent and manufacturing method thereof | |
| JP2010184916A (en) | Hair growth promoter | |
| CN112107527A (en) | Anti-hair loss essence and preparation method thereof | |
| JP2012020950A (en) | Inhibitor of endothelin action and whitening agent | |
| TW201517929A (en) | Methods and compositions for enhancing hair quality using blackberry extract | |
| CN107898656B (en) | Skin external composition containing ginsenoside RF | |
| JP6322368B2 (en) | Hair cosmetic and skin cosmetic containing PGD2 production inhibitor and 5α-reductase activity inhibitor | |
| KR20130036984A (en) | Cosmetic composition for inhibiting hair loss and enhanching hair growth | |
| JP6083938B2 (en) | Hair cosmetics | |
| JP3908245B2 (en) | Hair nourishing agent | |
| KR20170128766A (en) | Cosmetic Composition Containing Broussonetia Extract for Inhibiting Lipogenesis and Decreasing Sebum Secretion of Skin | |
| JP7161302B2 (en) | Wnt10b production promoter and scalp and hair cosmetic containing the same | |
| US20070207114A1 (en) | Hair Growth Agent Composition | |
| JP2003012472A (en) | Hair-growing agent | |
| JP2010095496A (en) | Production conditioner for hair-growing cytokine, and hair grower, quasi-drug and cosmetic each incorporated with production conditioner for growing the cytokine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160623 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171101 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180315 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180403 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180409 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6322368 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |